The_DT Treasury_NNP is_VBZ still_RB working_VBG out_RP the_DT details_NNS with_IN bank_NN trade_NN associations_NNS and_CC the_DT other_JJ government_NN agencies_NNS that_WDT have_VBP a_DT hand_NN in_IN fighting_VBG money_NN laundering_NN ._.
Among_IN the_DT possibilities_NNS the_DT Treasury_NNP is_VBZ considering_VBG are_VBP requirements_NNS that_IN banks_NNS keep_VB records_NNS identifying_VBG the_DT originators_NNS and_CC recipients_NNS of_IN international_JJ wire_NN transfers_NNS ._.
Another_DT suggestion_NN would_MD draw_VB banks_NNS more_RBR directly_RB into_IN tracking_VBG down_RP money_NN launderers_NNS by_IN developing_VBG a_DT ``_`` suspicious_JJ international_JJ wire_NN transfer_NN profile_NN ,_, ''_'' which_WDT banks_NNS would_MD use_VB to_TO spotlight_VB questionable_JJ payments_NNS ._.
But_CC banks_NNS may_MD prefer_VB using_VBG a_DT profile_NN that_WDT targets_VBZ selected_VBN transactions_NNS ,_, rather_RB than_IN a_DT blanket_NN reporting_NN requirement_NN ._.
Banks_NNS now_RB are_VBP required_VBN only_RB to_TO report_VB cash_NN deposits_NNS or_CC withdrawals_NNS of_IN $_$ 10,000_CD or_CC more_JJR ._.
But_CC wire_NN transfers_NNS from_IN a_DT standing_VBG account_NN --_: including_VBG those_DT bigger_JJR than_IN $_$ 10,000_CD --_: are_VBP n't_RB reported_VBN ._.
Officials_NNS believe_VBP this_DT has_VBZ left_VBN a_DT gaping_JJ loophole_NN that_IN illegal_JJ drug_NN businesses_NNS are_VBP exploiting_VBG ._.
Authorities_NNS estimate_VBP that_IN revenues_NNS from_IN illegal_JJ drugs_NNS in_IN the_DT U.S._NNP total_VBP about_RB $_$ 110_CD billion_CD annually_RB ._.
Sen._NNP John_NNP Kerry_NNP -LRB-_-LRB- D._NNP ,_, Mass._NNP -RRB-_-RRB- ,_, chairman_NN of_IN a_DT Senate_NNP Foreign_NNP Relations_NNP subcommittee_NN that_WDT oversees_VBZ the_DT issue_NN of_IN money_NN laundering_NN ,_, criticized_VBD the_DT proposal_NN for_IN ignoring_VBG wire_NN transfers_NNS between_IN foreign_JJ banks_NNS that_WDT are_VBP executed_VBN and_CC cleared_VBN on_IN U.S._NNP wire_NN systems_NNS ._.
The_DT American_NNP Bankers_NNP Association_NNP did_VBD n't_RB have_VB any_DT comment_NN on_IN the_DT plan_NN ._.
The_DT proposal_NN now_RB enters_VBZ a_DT 60-day_JJ comment_NN period_NN ,_, after_IN which_WDT the_DT Treasury_NNP will_MD propose_VB final_JJ regulations_NNS ,_, followed_VBN by_IN another_DT comment_NN period_NN ._.
Western_NNP Union_NNP Corp._NNP took_VBD steps_NNS to_TO withdraw_VB its_PRP$ proposed_VBN debt_NN swap_NN for_IN $_$ 500_CD million_CD in_IN high-interest_JJ notes_NNS and_CC said_VBD it_PRP is_VBZ looking_VBG at_IN other_JJ alternatives_NNS for_IN refinancing_VBG the_DT debt_NN ._.
Western_NNP Union_NNP had_VBD said_VBD two_CD weeks_NNS ago_RB that_IN it_PRP might_MD withdraw_VB the_DT pending_VBG offer_NN ,_, which_WDT would_MD have_VB replaced_VBN $_$ 500_CD million_CD in_IN so-called_JJ reset_JJ notes_NNS ,_, now_RB paying_VBG 19.25_CD %_NN annual_JJ interest_NN and_CC set_VBN to_TO come_VB due_RB in_IN 1992_CD ,_, with_IN two_CD new_JJ issues_NNS paying_VBG lower_JJR interest_NN ._.
Yesterday_NN the_DT company_NN said_VBD it_PRP had_VBD filed_VBN a_DT request_NN with_IN the_DT Securities_NNP and_CC Exchange_NNP Commission_NNP to_TO withdraw_VB the_DT registration_NN statement_NN regarding_VBG the_DT proposed_VBN swap_NN ._.
A_DT Western_NNP Union_NNP spokesman_NN ,_, citing_VBG adverse_JJ developments_NNS in_IN the_DT market_NN for_IN high-yield_JJ ``_`` junk_NN ''_'' bonds_NNS ,_, declined_VBD to_TO say_VB what_WP alternatives_NNS are_VBP under_IN consideration_NN ._.
But_CC some_DT holders_NNS of_IN the_DT Western_NNP Union_NNP notes_NNS expect_VBP the_DT company_NN to_TO propose_VB a_DT more-attractive_JJ debt_NN swap_NN that_WDT will_MD give_VB them_PRP a_DT substantial_JJ equity_NN stake_NN in_IN the_DT company_NN ._.
Western_NNP Union_NNP has_VBZ had_VBD major_JJ losses_NNS in_IN recent_JJ years_NNS as_IN its_PRP$ telex_NN business_NN has_VBZ faltered_VBN in_IN the_DT face_NN of_IN competition_NN from_IN facsimile_NN machines_NNS and_CC as_RB other_JJ business_NN ventures_NNS have_VBP gone_VBN awry_RB ._.
The_DT major_JJ question_NN ,_, said_VBD one_CD holder_NN who_WP asked_VBD not_RB to_TO be_VB named_VBN ,_, is_VBZ whether_IN New_NNP York_NNP investor_NN Bennett_NNP S._NNP LeBow_NNP ,_, whose_WP$ Brooke_NNP Partners_NNP controls_VBZ Western_NNP Union_NNP ,_, is_VBZ willing_JJ to_TO offer_VB a_DT large_JJ enough_RB equity_NN stake_NN to_TO entice_VB bondholders_NNS into_IN agreeing_VBG to_TO a_DT new_JJ swap_NN ._.
The_DT $_$ 500_CD million_CD in_IN notes_NNS ,_, the_DT largest_JJS chunk_NN of_IN Western_NNP Union_NNP 's_POS $_$ 640_CD million_CD in_IN long-term_JJ debt_NN ,_, stems_VBZ from_IN the_DT company_NN 's_POS major_JJ restructuring_NN in_IN December_NNP 1987_CD ._.
The_DT notes_NNS became_VBD burdensome_JJ when_WRB reset_NN provisions_NNS allowed_VBD their_PRP$ interest_NN rate_NN to_TO be_VB raised_VBN to_TO 19.25_CD %_NN last_JJ June_NNP ._.
Western_NNP Union_NNP had_VBD offered_VBN to_TO swap_VB each_DT $_$ 1,000_CD face_NN amount_NN of_IN the_DT notes_NNS for_IN six_CD shares_NNS of_IN common_JJ stock_NN and_CC two_CD new_JJ debt_NN issues_NNS :_: a_DT $_$ 500_CD note_NN paying_VBG an_DT interest_NN rate_NN starting_VBG at_IN 16.75_CD %_NN annually_RB and_CC rising_VBG in_IN later_JJ years_NNS ,_, due_RB in_IN 1992_CD ,_, and_CC a_DT $_$ 500_CD note_NN ,_, due_RB in_IN 1997_CD ,_, paying_VBG a_DT fixed_VBN rate_NN of_IN 17_CD %_NN and_CC including_VBG rights_NNS protecting_VBG a_DT holder_NN against_IN a_DT decline_NN in_IN the_DT trading_NN price_NN of_IN the_DT bond_NN ._.
Western_NNP Union_NNP must_MD make_VB $_$ 48_CD million_CD in_IN interest_NN payments_NNS on_IN the_DT reset_NN notes_NNS on_IN Dec._NNP 15_CD ,_, and_CC a_DT company_NN spokesman_NN said_VBD it_PRP fully_RB intends_VBZ to_TO meet_VB the_DT payments_NNS ._.
But_CC Western_NNP Union_NNP has_VBZ said_VBD it_PRP must_MD lower_VB the_DT interest_NN rate_NN on_IN its_PRP$ debt_NN to_TO regain_VB full_JJ financial_JJ health_NN ._.
Genentech_NNP Inc._NNP said_VBD the_DT West_NNP German_NNP distributor_NN of_IN its_PRP$ heart_NN drug_NN TPA_NNP reached_VBD a_DT joint_NN marketing_NN agreement_NN with_IN a_DT subsidiary_NN of_IN Hoechst_NNP AG_NNP ,_, which_WDT makes_VBZ the_DT rival_JJ anti-clotting_JJ agent_NN streptokinase_NNP ._.
The_DT biotechnology_NN concern_NN said_VBD the_DT agreement_NN between_IN its_PRP$ longtime_NN West_NNP German_NNP distributor_NN ,_, Boehringer-Ingleheim_NNP 's_POS Dr._NNP Karl_NNP Thomae_NNP G.m.b.H._NNP subsidiary_NN ,_, and_CC Hoechst_NNP 's_POS Behringwerke_NNP subsidiary_NN was_VBD an_DT attempt_NN to_TO expand_VB the_DT market_NN for_IN blood-clot_NN drugs_NNS in_IN general_NN ._.